Jump to content

Template:Oral hypoglycemics and insulin analogs: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
add SGLT2 inhibitors
Tag: Reverted
Undid revision 1189664915 by Whywhenwhohow (talk) Why twice each SGLT2 inhibitor on the same line?
Line 10: Line 10:
| group1 = ''fast-acting''
| group1 = ''fast-acting''
| list1=
| list1=
* [[Insulin aspart]]
*[[Insulin aspart]]
* [[Insulin glulisine]]
*[[Insulin glulisine]]
* [[Insulin lispro]]
*[[Insulin lispro]]
| group2 = ''short-acting''
| group2 = ''short-acting''
| list2 =
| list2 =
* [[Regular insulin]]<sup>#</sup>
*[[Regular insulin]]<sup>#</sup>


| group3 = ''long-acting''
| group3 = ''long-acting''
| list3 =
| list3 =
* [[Insulin detemir]]<sup>#</sup>
*[[Insulin detemir]]<sup>#</sup>
* [[Insulin glargine]]<sup>#</sup> ([[Insulin glargine/lixisenatide|+lixisenatide]])
*[[Insulin glargine]]<sup>#</sup> ([[Insulin glargine/lixisenatide|+lixisenatide]])
* [[NPH insulin]]
*[[NPH insulin]]
* [[Lente insulin]]<sup>‡</sup>
*[[Lente insulin]]<sup>‡</sup>
* [[Ultralente insulin]]<sup>‡</sup>
*[[Ultralente insulin]]<sup>‡</sup>


| group4 = ''ultra-long-acting''
| group4 = ''ultra-long-acting''
| list4 =
| list4 =
* [[Insulin degludec]]<sup>#</sup> ([[Insulin degludec/insulin aspart|+insulin aspart]], [[Insulin degludec/liraglutide|+liraglutide]])
*[[Insulin degludec]]<sup>#</sup> ([[Insulin degludec/insulin aspart|+insulin aspart]], [[Insulin degludec/liraglutide|+liraglutide]])
* [[Insulin icodec]]<sup>†</sup> ([[Insulin icodec/semaglutide|+semaglutide]])
*[[Insulin icodec]]<sup>†</sup> ([[Insulin icodec/semaglutide|+semaglutide]])


| group5 = ''[[Inhalable insulin|inhalable]]''
| group5 = ''[[Inhalable insulin|inhalable]]''
| list5 =
| list5 =
* Exubera<sup>‡</sup>
*Exubera<sup>‡</sup>
* Afrezza
*Afrezza
}}
}}
{{PharmNavFootnote}}
{{PharmNavFootnote}}
Line 45: Line 45:
| group1 = [[Biguanide]]s
| group1 = [[Biguanide]]s
| list1 =
| list1 =
* [[Buformin]]<sup>‡</sup>
*[[Buformin]]<sup>‡</sup>
* [[Metformin]]<sup>#</sup>
*[[Metformin]]<sup>#</sup>
* [[Phenformin]]<sup>‡</sup>
*[[Phenformin]]<sup>‡</sup>


| group2 = [[Thiazolidinedione|TZD]]s/"glitazones" ([[PPAR agonist|PPAR]])
| group2 = [[Thiazolidinedione|TZD]]s/"glitazones" ([[PPAR agonist|PPAR]])
| list2 =
| list2 =
* [[Ciglitazone]]<sup>§</sup>
*[[Ciglitazone]]<sup>§</sup>
* [[Darglitazone]]<sup>§</sup>
*[[Darglitazone]]<sup>§</sup>
* [[Englitazone]]<sup>§</sup>
*[[Englitazone]]<sup>§</sup>
* [[Lobeglitazone]]
*[[Lobeglitazone]]
* [[Netoglitazone]]<sup>§</sup>
*[[Netoglitazone]]<sup>§</sup>
* [[Pioglitazone]]
*[[Pioglitazone]]
* [[Rivoglitazone]]<sup>†</sup>
*[[Rivoglitazone]]<sup>†</sup>
* [[Rosiglitazone]]
*[[Rosiglitazone]]
* [[Troglitazone]]<sup>‡</sup>
*[[Troglitazone]]<sup>‡</sup>


| group3 = [[PPAR agonist#Dual PPAR agonists|Dual PPAR agonists]]
| group3 = [[PPAR agonist#Dual PPAR agonists|Dual PPAR agonists]]
| list3 =
| list3 =
* [[Aleglitazar]]<sup>†</sup>
*[[Aleglitazar]]<sup>†</sup>
* [[Muraglitazar]]<sup>§</sup>
*[[Muraglitazar]]<sup>§</sup>
* [[Saroglitazar]]
*[[Saroglitazar]]
* [[Tesaglitazar]]<sup>§</sup>
*[[Tesaglitazar]]<sup>§</sup>




| group4 = [[Amylin]] analogs and [[DACRA]]s
| group4 = [[Amylin]] analogs and [[DACRA]]s
| list4 =
| list4 =
* [[Cagrilintide]]<sup>§</sup>
*[[Cagrilintide]]<sup>§</sup>
* [[Pramlintide]]
*[[Pramlintide]]
}}
}}


Line 84: Line 84:
| group1 = [[Sulfonylurea]]s
| group1 = [[Sulfonylurea]]s
| list1 =
| list1 =
* ''1st generation'': [[Acetohexamide]]
*''1st generation'': [[Acetohexamide]]
* [[Carbutamide]]
*[[Carbutamide]]
* [[Chlorpropamide]]
*[[Chlorpropamide]]
* [[Glycyclamide]]
*[[Glycyclamide]]
* [[Metahexamide]]
*[[Metahexamide]]
* [[Tolazamide]]
*[[Tolazamide]]
* [[Tolbutamide]]
*[[Tolbutamide]]


* ''2nd generation'': [[Glibenclamide|Glibenclamide (glyburide)]]
*''2nd generation'': [[Glibenclamide|Glibenclamide (glyburide)]]
* [[Glibornuride]]
*[[Glibornuride]]
* [[Glicaramide]]
*[[Glicaramide]]
* [[Gliclazide]]<sup>#</sup>
*[[Gliclazide]]<sup>#</sup>
* [[Glimepiride]]
*[[Glimepiride]]
* [[Glipizide]]
*[[Glipizide]]
* [[Gliquidone]]
*[[Gliquidone]]
* [[Glisoxepide]]
*[[Glisoxepide]]
* [[Glyclopyramide]]
*[[Glyclopyramide]]


| group2 = [[Meglitinide]]s/"glinides"
| group2 = [[Meglitinide]]s/"glinides"
| list2 =
| list2 =
* [[Mitiglinide]]
*[[Mitiglinide]]
* [[Nateglinide]]
*[[Nateglinide]]
* [[Repaglinide]]
*[[Repaglinide]]


}}
}}
Line 112: Line 112:
| group2 = [[Glucagon-like peptide-1 receptor agonist|GLP-1 receptor agonists]]
| group2 = [[Glucagon-like peptide-1 receptor agonist|GLP-1 receptor agonists]]
| list2 =
| list2 =
* [[Albiglutide]]<sup>‡</sup>
*[[Albiglutide]]<sup>‡</sup>
* [[Danuglipron]]<sup>†</sup>
*[[Danuglipron]]<sup>†</sup>
* [[Dulaglutide]]
*[[Dulaglutide]]
* [[Exenatide]]
*[[Exenatide]]
* [[Liraglutide]]
*[[Liraglutide]]
* [[Lixisenatide]]
*[[Lixisenatide]]
* [[Orforglipron]]<sup>§</sup>
*[[Orforglipron]]<sup>§</sup>
* [[Semaglutide]]
*[[Semaglutide]]
* [[Taspoglutide]]<sup>†</sup>
*[[Taspoglutide]]<sup>†</sup>
{{navbox|child|
{{navbox|child|
group1=[[GLP1 poly-agonist peptides]]
group1=[[GLP1 poly-agonist peptides]]
Line 130: Line 130:
| group3 = [[Dipeptidyl peptidase-4 inhibitor|DPP-4 inhibitor]]s/"gliptins"
| group3 = [[Dipeptidyl peptidase-4 inhibitor|DPP-4 inhibitor]]s/"gliptins"
| list3 =
| list3 =
* [[Alogliptin]]
*[[Alogliptin]]
* [[Anagliptin]]
*[[Anagliptin]]
* [[Evogliptin]]
*[[Evogliptin]]
* [[Garvagliptin]]
*[[Garvagliptin]]
* [[Gemigliptin]]
*[[Gemigliptin]]
* [[Gosogliptin]]
*[[Gosogliptin]]
* [[Linagliptin]]
*[[Linagliptin]]
* [[Melogliptin]]
*[[Melogliptin]]
* [[Omarigliptin]]
*[[Omarigliptin]]
* [[Saxagliptin]]
*[[Saxagliptin]]
* [[Sitagliptin]]
*[[Sitagliptin]]
* [[Teneligliptin]]
*[[Teneligliptin]]
* [[Trelagliptin]]
*[[Trelagliptin]]
* [[Vildagliptin]]
*[[Vildagliptin]]
}}
}}
|group3 = Other
|group3 = Other
Line 149: Line 149:
| group1 = [[Aldose reductase inhibitor]]s
| group1 = [[Aldose reductase inhibitor]]s
| list1 =
| list1 =
* [[Epalrestat]]
*[[Epalrestat]]
* [[Fidarestat]]<sup>§</sup>
*[[Fidarestat]]<sup>§</sup>
* [[Ranirestat]]<sup>†</sup>
*[[Ranirestat]]<sup>†</sup>
* [[Tolrestat]]<sup>‡</sup>
*[[Tolrestat]]<sup>‡</sup>
* [[Zenarestat]]<sup>§</sup>
*[[Zenarestat]]<sup>§</sup>


| group2 = [[Alpha-glucosidase inhibitor]]s
| group2 = [[Alpha-glucosidase inhibitor]]s
| list2 =
| list2 =
* [[Acarbose]]
*[[Acarbose]]
* [[Miglitol]]
*[[Miglitol]]
* [[Voglibose]]
*[[Voglibose]]


| group4 = [[Gliflozin|SGLT2 inhibitors]]/"gliflozins"
| group4 = [[Gliflozin|SGLT2 inhibitors]]/"gliflozins"
| list4 =
| list4 =
* [[Canagliflozin]]
*[[Canagliflozin]]
* [[Dapagliflozin]]
*[[Dapagliflozin]]
* [[Empagliflozin]]<sup>#</sup>
*[[Empagliflozin]]<sup>#</sup>
* [[Ertugliflozin]]
*[[Ertugliflozin]]
* [[Ipragliflozin]]
*[[Ipragliflozin]]
* [[Luseogliflozin]]
*[[Luseogliflozin]]
* [[Remogliflozin etabonate|Remogliflozin]]<sup>§</sup>
*[[Remogliflozin etabonate|Remogliflozin]]<sup>§</sup>
* [[Sergliflozin etabonate|Sergliflozin]]<sup>§</sup>
*[[Sergliflozin etabonate|Sergliflozin]]<sup>§</sup>
* [[Tofogliflozin]]<sup>†</sup>
*[[Tofogliflozin]]<sup>†</sup>
* [[Dapagliflozin]]
* [[Canagliflozin]]
* [[Empagliflozin]]
* [[Ertugliflozin]]
* [[Ipragliflozin]]
* [[Sotagliflozin]]
* [[Luseogliflozin]]
* [[Velagliflozin]]


| group5 = Other
| group5 = Other
| list5 =
| list5 =
* [[Benfluorex]]<sup>‡</sup>
*[[Benfluorex]]<sup>‡</sup>
* [[Bromocriptine]]
*[[Bromocriptine]]
* [[Imeglimin]]
*[[Imeglimin]]
}}
}}
|group4 = [[Combination drug|Combinations]]
|group4 = [[Combination drug|Combinations]]
Line 192: Line 184:
* [[Alogliptin/metformin]]
* [[Alogliptin/metformin]]
* [[Canagliflozin/metformin]]
* [[Canagliflozin/metformin]]
* [[Cagrilintide/semaglutide]]<sup>§</sup>
*[[Cagrilintide/semaglutide]]<sup>§</sup>
* [[Dapagliflozin/metformin]]
* [[Dapagliflozin/metformin]]
* [[Dapagliflozin/saxagliptin]]
* [[Dapagliflozin/saxagliptin]]
Line 219: Line 211:
* [[Simvastatin/sitagliptin|Sitagliptin/simvastatin]]
* [[Simvastatin/sitagliptin|Sitagliptin/simvastatin]]
* [[Vildagliptin/metformin]]
* [[Vildagliptin/metformin]]

}}
}}
}}
}}

Revision as of 07:37, 13 December 2023

This template's initial visibility currently defaults to autocollapse, meaning that if there is another collapsible item on the page (a navbox, sidebar, or table with the collapsible attribute), it is hidden apart from its title bar; if not, it is fully visible.

To change this template's initial visibility, the |state= parameter may be used:

  • {{Oral hypoglycemics and insulin analogs|state=collapsed}} will show the template collapsed, i.e. hidden apart from its title bar.
  • {{Oral hypoglycemics and insulin analogs|state=expanded}} will show the template expanded, i.e. fully visible.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Template:Oral_hypoglycemics_and_insulin_analogs&oldid=1189668135"